About Vivoryon
Vivoryon is a company based in Halle (Germany) founded in 1997. The company has 15 employees as of December 31, 2024. Vivoryon offers products and services including varoglutamstat. Vivoryon operates in a competitive market with competitors including T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
- Headquarter Halle, Germany
- Employees 15 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vivoryon Therapeutics N.V.
-
Annual Revenue
Not available
-
Net Profit
-$21.37 M (USD)27.43as on Dec 31, 2024
-
EBITDA
-$21.62 M (USD)28.63as on Dec 31, 2024
-
Latest Funding Round
$5.99 M (USD), Post-IPO
Oct 06, 2025
-
Investors
Not available
-
Employee Count
15
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vivoryon
Vivoryon is a publicly listed company on the EURONEXT with ticker symbol VVY in Netherlands, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vivoryon
Vivoryon offers a comprehensive portfolio of products and services, including varoglutamstat.
Inhibits enzymes to treat inflammation and neurodegeneration in severe diseases.
Funding Insights of Vivoryon
Investments & Acquisitions by Vivoryon
Investment portfolio details for Vivoryon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vivoryon
Detailed financials for Vivoryon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vivoryon Comparisons
Peer comparison for Vivoryon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vivoryon
Vivoryon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Alzheon, Longeveron, Alchemab and Cerecin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Medical foods and drugs for Alzheimer's disease are developed.
|
|
| Locked | Locked | Locked |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
Detailed competitors of Vivoryon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vivoryon
Complete news archive for Vivoryon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vivoryon
Vivoryon was founded in 1997 and raised its 1st funding round 18 years after it was founded.
Vivoryon is headquartered in Halle, Germany. It is registered at Halle, Sachsen-anhalt, Germany.
Ulrich Dauer is the current CEO of Vivoryon.
As of Dec 31, 2024, the latest employee count at Vivoryon is 15.
Vivoryon Therapeutics was founded in 1997 in Halle, Germany, where small molecule inhibitors targeting glutaminyl cyclase enzymes are developed for age-related conditions. The lead candidate, PQ912, is in phase 2a clinical trials for Alzheimers disease and cancer. Additional preclinical candidates, such as PQ1565, address cancer and related disorders by inhibiting key enzymes in disease pathways. Operations focus on biotechnology for therapeutic innovation in neurology and oncology.
Vivoryon's top competitors include Alzheon, Longeveron and Alchemab.
Vivoryon offers varoglutamstat.
Yes, Vivoryon is publicly traded on EURONEXT under the ticker symbol VVY.
The ticker symbol of Vivoryon is VVY on EURONEXT.